The New Mounjaro Rule: What It Means for UK Patients

What exactly is the new Mounjaro rule that people are searching for?

The shorthand "new Mounjaro rule" refers to the phased NHS commissioning framework for tirzepatide in England, which flows from NICE's appraisal TA1026, published in December 2024. NICE found tirzepatide clinically and cost-effective for weight management, but recommended it be rolled out gradually so NHS services can cope with demand. The result is a sequence of eligibility cohorts, each unlocking access to a slightly broader group of patients.

The rule matters because it determines who can receive Mounjaro through their GP or specialist weight management service without paying privately. It does not affect the medicine's authorised licence, which is set by the MHRA and permits private prescription for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea.

The phrase "new rule" also circulates in connection with Eli Lilly's revised UK list price, which rose substantially from 1 September 2025. That is a separate development (a commercial pricing decision rather than a regulatory change) though it has affected what private providers charge. A fuller breakdown of what these shifts mean for cost is on the Mounjaro cost and price page.

What are the specific NHS eligibility thresholds under the new rule?

NICE's TA1026 recommendation sets out a staged rollout rather than a single launch moment. Each cohort has its own BMI floor and a minimum number of qualifying conditions from a defined list of five: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

The first cohort opened in June 2025, covering adults with a BMI of 40 or above plus four or more of those five conditions. The second cohort activated in June 2026, extending access to adults with a BMI between 35 and 39.9 alongside four or more conditions. A further cohort is expected around March 2027, covering a BMI of 40 or above with three qualifying conditions. The schedule continues after that, progressively lowering the barrier.

Throughout the rollout, people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds benefit from BMI thresholds that are 2.5 kg/m² lower at each stage, a recognition that health risk associated with excess weight differs across ethnic groups. Even meeting the stated thresholds does not guarantee NHS treatment; patients must also take part in a supported diet and activity programme, and availability can vary between GP practices and integrated care boards.

Details on how new customers access Mounjaro (both privately and through NHS routes) are covered separately.

Does the new rule affect people who already take Mounjaro privately?

For people already using tirzepatide through a private pharmacy, the NHS commissioning rule has no direct bearing. Private prescriptions continue to be governed by the MHRA-approved licence and the prescriber's clinical judgement. What has changed for private patients is mainly the cost landscape: the list-price increase from Eli Lilly in late 2025 fed through to private pharmacy pricing, so monthly costs are generally higher than they were before September 2025.

A subtler change is the volume of discussion around the new NHS rule itself, which has prompted many people to check whether they might now qualify on the NHS. If you are privately prescribed and think you may meet the current NHS criteria, talking to your GP is the right first step, they can assess whether your local integrated care board is actively commissioning in your cohort. Some GP practices began prescribing under the updated GP contract from April 2026, though participation varies.

People who are new to tirzepatide and want to understand what starting on it involves, from the titration schedule to storage, will find that process unchanged by the NHS access rule. A starter pen contains four weekly doses at 2.5 mg; your prescriber maps out the titration from there.

What arrives, and how does a private prescription route work in practice?

If someone does not meet the current NHS cohort criteria, or cannot access NHS prescribing locally, a regulated private pharmacy is the alternative. At nume, that starts with a free consultation reviewed the same day by a GPhC-registered Independent Prescriber, a named clinician, not automated software. Identity and weight are verified before approval. If clinically suitable and the order is placed before 12pm, the treatment is dispatched the same day and arrives the following working day with DPD. It comes in plain, unbranded packaging: a discrete box, a tracking notification on your phone, the KwikPen inside.

The GPhC register, searchable at registration number 9012878, confirms our pharmacy's standing. Any pharmacy offering these medicines without requiring a prescription from a qualified clinician should be treated as a serious red flag; counterfeit pens have caused harm in the UK, and the MHRA has a Yellow Card route for reporting suspect sellers.

If you want to understand more about Mounjaro as a treatment before deciding, or have a specific question about which rules apply to your situation, those pages cover both in detail. When you're ready, check your eligibility with our clinical team.